What is the translation of " REPEAT DOSE " in Croatian?

• ponovljenih doza
• ponovljene doze

Examples of using Repeat dose in English and their translations into Croatian

A repeat dose 0.3 to 0.5 mg/kg body weight, i.e.
Ponovljenu dozu 0, 3 do 0, 5 mg/kg tjelesne težine, tj.

They may also be given a repeat dose after one hour.
Njima se može također dati ponovljena doza nakon sat vremena.

In repeat dose studies in dogs, haemolytic anaemia was not observed.
U ispitivanjima ponovljene doze u pasa nije bila opažena hemolitička anemija.

No conventional acute and repeat dose toxicity studies were performed.
Nisu provedene konvencionalne studije o akutnoj toksičnosti i toksičnosti nakon ponovljenih doza.

No hepatotoxicity was observed in rodents and monkeys in the repeat dose toxicity studies.
Kod glodavaca i majmuna nije zamijećena hepatotoksičnost u studijama toksičnosti ponovljenih doza.

Single dose and repeat dose studies in a range of animal models(rats, dogs and primates) were performed.
Provedene su studije jednokratnih i ponavljanih doza na više životinjskih modela štakori, psi i primati.

No evidence of an associated risk was identified in the rat and monkey repeat dose toxicity studies.
U ispitivanjima toksičnosti ponovljene doze u štakora i majmuna nije pronađen nikakav dokaz s time povezanog rizika.

Other long-term repeat dose and carcinogenicity studies revealed no clinically relevant changes.
U drugim dugoročnim ispitivanjima s ponovljenim dozama i ispitivanjima kancerogenosti nisu otkrivene klinički relevantne promjene.

Non-clinical studies demonstrated minor alterations in liver enzymes and calcium levels in a repeat dose toxicity study in rats.
Neklinička ispitivanja pokazala su manje promjene razina jetrenih enzima i kalcija u ispitivanju toksičnosti ponovljene doze na štakorima.

Repeat dose toxicity studies longer than 5 days, reproductive toxicity studies and carcinogenicity studies, have not been performed.
Ispitivanja toksičnosti ponovljenih doza dulja od 5 dana, ispitivanja reproduktivne toksičnosti i ispitivanja kancerogenosti nisu provedena.

If you have not responded sufficiently to treatment after 7 days, your doctor may consider giving you a repeat dose of 150 mg or 2 mg/kg.
Ako niste imali dostatan odgovor na liječenje nakon 7 dana, Vaš liječnik može razmotriti primjenu ponovljene doze od 150 mg ili 2 mg/kg.

Repeat dose toxicity studies in animals have shown that bevacizumab may have an adverse effect on female fertility see section 5.3.
Ispitivanja toksičnosti ponovljenih doza provedena na životinjama pokazala su da bevacizumab može imati štetan učinak na žensku plodnost vidjeti dio 5.3.

There were no notable effects in the male and female reproductive organs in monkeys based on 1-month and 6-month repeat dose toxicity studies see section 5.3.
U 1-mjesečnim i 6-mjesečnim ispitivanjima toksičnosti ponovljenih doza nisu zabilježeni primjetni učinci na reproduktivne organe mužjaka i ženki majmuna vidjeti dio 5.3.

However, results from a repeat dose toxicity study suggest there is a potential for aflibercept to impair reproductive function and fertility.
Međutim, rezultati ispitivanja toksičnosti ponovljenih doza ukazuju na to da bi aflibercept mogao poremetiti reproduktivnu funkciju i plodnost.

Fertility studies with trabectedin were not performed but limited histopathological changes were observed in the gonads in the repeat dose toxicity studies.
Ispitivanja plodnosti s trabektedinom nisu provedena, ali ograničene histopatološke promjene primijećene su na gonadama u ispitivanjima toksičnosti s ponovljenim dozama.

Repeat dose toxicity studies with estradiol, nomegestrol acetate or combination have indicated expected estrogenic and gestagen effects.
Ispitivanja toksičnosti ponovljenih doza estradiola, nomegestrolacetata ili njihove kombinacije ukazala su na očekivane učinke estrogena i gestagena.

Effects on male and female fertility in monkeys were assessed in the 6-month repeat dose toxicology studies of belimumab at doses up to and including 50 mg/kg.
Učinci na mušku i žensku plodnost u majmuna bili su procijenjeni u 6-mjesečnim toksikološkim studijama ponovljenih doza belimumaba, s dozama do, i uključujući, 50 mg/kg.

In repeat dose toxicity studies in mouse, rat, dog and the cynomolgus monkey main target organs of toxicity were the ovary, uterus and the liver.
U ispitivanjima toksičnosti ponovljenih doza na miševima, štakorima, psima i makaki majmunima, glavni ciljni organi toksičnosti bili su jajnik, maternica i jetra.

Pre-clinical data reveal no special hazard for humans based on studies for acute toxicology, repeat dose toxicity, genotoxicity, carcinogenic potential and local toxicity.
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju ispitivanja akutne toksičnosti, toksičnosti ponovljenih doza, genotoksičnosti, kancerogenosti i lokalne toksičnosti.

However, in repeat dose studies, testicular degeneration/depletion was seen in rats and dogs≥0.2 times the human clinical exposure based on AUC.
Međutim, u ispitivanjima s ponovljenim dozama, u štakora i pasa je uočena testikularna degeneracija/deplecija ≥ 0, 2 puta kliničke izloženosti u ljudi temeljeno na AUC-u.

Non-Clinical data obtained with Celvapan containing a H5N1 vaccine strain demonstrated alterations in liver enzymes and calcium levels in repeat dose toxicity studies in rats.
Neklinički podaci dobiveni s Celvapanom koji sadrži soj cjepiva H5N1 pokazali su promjene u enzimima jetre i razinama kalcija u ispitivanjima toksičnosti ponovljene doze na štakorima.

A repeat dose toxicity study in rats, which included an evaluation of single-dose toxicity and local tolerance, revealed no special hazards to humans.
Ispitivanja ponovljenih doza u štakora, koja su uključila i procjenu toksičnosti jednokratne doze i lokalnu podnošljivost, nisu ukazala na poseban rizik za ljude.

No effects were seen on male or female reproductive organs in repeat dose toxicology studies in mice, rats or monkeys with levodopa alone, or in combination with carbidopa.
Nisu uočeni učinci na muške ili ženske reproduktivne organe u ispitivanjima toksičnosti ponovljene doze u miševa, štakora ili majmuna samo s levodopom ili u kombinaciji s karbidopom.

In a repeat dose study with 12 patients receiving Abraxane administered intravenously at 260 mg/m2, intrapatient variability in AUC was 19% range 3.21%-37.70.
U ispitivanjima ponovljene doze s 12 bolesnika koji su primali Abraxane intravenski u dozi od 260 mg/m2, varijabilnost između bolesnika u vrijednosti AUC-a iznosila je 19% raspon 3,21%- 37, 70.

In rats, vacuolation of the renal pelvic epithelium as well as vacuolation and thickening(hyperplasia) of the bladder epithelium were observed in 26-week repeat dose studies.
U štakora je u ispitivanjima ponovljene doze koja su trajala 26 tjedana opažena vakuolizacija epitela bubrežne nakapnice, kao i vakuolizacija i zadebljanje(hiperplazija) epitela mokraćnog mjehura.

Maximum doses in repeat dose toxicity studies were limited by the exaggerated pharmacologic effects of retigabine including ataxia, hypokinesia and tremor.
Najviše doze u ispitivanjima toksičnosti ponavljajućih doza bile su ograničene prekomjernim farmakološkim učincima retigabina uključujući ataksiju, hipokineziju i tremor.

Non-clinical data reveal no special hazard for humans based on conventional studies of repeat dose toxicity, genotoxicity and carcinogenic potential, including one photocarcinogenicity study in mice.
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja toksičnosti ponovljenih doza, genotoksičnosti, kancerogenosti, uključujući i jednu studiju fotokancerogenosti na miševima.

Following the repeat dose administration at the recommended dose, siltuximab clearance was found to be time-invariant, and systemic accumulation was moderate accumulation index of 1.7.
Nakon primjene ponovljene doze pri preporučenoj dozi, otkriveno je da je klirens siltuksimaba neovisan o vremenu, a sistemsko nakupljanje bilo je umjereno indeks nakupljanja od 1, 7.

Echocardiography revealed no indication of cardiac decompensation in a repeat dose safety pharmacology study in rats at a systemic exposure 1.4-fold greater than that achieved therapeutically.
U farmakološkom ispitivanju sigurnosti ponovljenih doza u štakora, ehokardiografijom nisu utvrđeni znakovi dekompenzacije srca pri sustavnoj izloženosti 1, 4 puta većoj od one koja se postiže tijekom liječenja.

In repeat dose studies conducted in animals, the toxicity profile of Caelyx appears very similar to that reported in humans who receive long-term infusions of standard doxorubicin hydrochloride.
U ispitivanjima toksičnosti ponovljene doze na životinjama, profil toksičnosti Caelyxa čini se vrlo sličnim profilu zabilježenom u ljudi koji dugotrajno primaju infuzije standardnog doksorubicinklorida.